Condition: Multiple Myeloma · Cancer · Sponsor: UNC Lineberger Comprehensive Cancer Center
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.
This description comes directly from the study's public registry record.
Shamina Williams · 919-966-4432 · Shamina_Williams@med.unc.edu
Lori Stravers · 919-966-4432 · Lori_Stravers@med.unc.edu
Always discuss trial participation with your own doctor first.
| University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| Duke Comprehensive Cancer Center | Durham, North Carolina, United States | Recruiting |
| Novant Health New Hanover Regional Medical Center | Wilmington, North Carolina, United States | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05145400